Laponis Adam 4

What Happened
Adam Laponis, Chief Financial Officer of Twist Bioscience (TWST), reported the sale of 4,000 common shares on May 29, 2026. The shares were sold at $70.00 per share for total gross proceeds of $280,000. The filing reports the transaction under code "S" (sale).

Key Details

• Transaction date: 2026-05-29; Sale price: $70.00 per share; Shares sold: 4,000; Total: $280,000.
• Report filed: 2026-06-02 (filed within the required two business days).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: Transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025 (pre-arranged plan).

Context

• Sales under a 10b5-1 plan are pre-scheduled and generally indicate the trade followed a pre-existing plan rather than a contemporaneous decision based on material nonpublic information.
• Sales are more routine than purchases for signaling intent; this single, planned sale does not by itself indicate a change in insider sentiment about the company.